Get the Stockscreener App
0.8476
5.70%
-0.0512
After Hours:
.85
0.0024
+0.28%
Adicet Bio Inc Stock (ACET) Latest News
Can Adicet's Novel CAR T Therapy Revolutionize Renal Cancer Treatment? New Data Coming - StockTitan
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting - Joplin Globe
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
Adicet Bio's (ACET) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
FDA fast tracks Adicet Bio's autoimmune therapy By Investing.com - Investing.com South Africa
FDA fast tracks Adicet Bio’s autoimmune therapy - Investing.com
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) - Lelezard
Adicet's Systemic Sclerosis Therapy Earns Critical FDA Fast Track StatusWhat This Means for Patients - StockTitan
Adicet Bio (NASDAQ:ACET) versus Corvus Pharmaceuticals (NASDAQ:CRVS) Head to Head Analysis - Defense World
Adicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com Nigeria
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com
Healthy Upside Potential: Adicet Bio Inc (ACET) - SETE News
Adicet Bio Inc [ACET] Insider Activity: An Update for Investors - Knox Daily
Investor Alert: What’s Really Going On At Adicet Bio Inc (NASDAQ: ACET) - Stocks Register
Adicet Bio (NASDAQ:ACET) Earns Market Perform Rating from JMP Securities - MarketBeat
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $7.50 - MarketBeat
Adicet Bio reports progress in clinical trial enrollments - MSN
HC Wainwright Reaffirms Neutral Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat
Adicet Bio (NASDAQ:ACET) Earns “Market Perform” Rating from JMP Securities - Defense World
Top investors say Adicet Bio Inc (ACET) ticks everything they need - SETE News
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease - geneonline
Adicet Bio Inc [NASDAQ: ACET] Sees Increase in Stock Value - Knox Daily
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth? - Simply Wall St
Adicet Bio reports progress in clinical trial enrollments By Investing.com - Investing.com Australia
Adicet Bio Inc (ACET) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Adicet Bio Inc (ACET) Stock Price and Analyst Predictions - The News Heater
What is ACET’s price-to-sales ratio telling us about the company’s value? - US Post News
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Marketscreener.com
Revolutionary Lupus Treatment Gets FDA Fast-Track: Adicet's ADI-001 Could Transform Patient Care - StockTitan
JPMorgan Chase & Co. Boosts Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Sparks Excitement with Major Stock Options Award for New Hires! - Mi Valle
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet's New CMO Receives 750,000 Share Options Package as Company Bolsters Leadership - StockTitan
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy - MSN
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - Business Wire
HC Wainwright & Co. Downgrades Adicet Bio (ACET) - MSN
Adicet Bio, Inc. (NASDAQ:ACET) Shares Sold by Jane Street Group LLC - Defense World
Geode Capital Management LLC Increases Position in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
Adicet Bio Advances First Gamma Delta CAR T Cell Therapy for Solid Tumors, Expands Autoimmune Trial - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Stake Reduced by State Street Corp - Defense World
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Bio (NASDAQ:ACET) Stock Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Adicet Bio (NASDAQ:ACET) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy - GlobeNewswire Inc.
Adicet Bio (NASDAQ:ACET) Earns Neutral Rating from HC Wainwright - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Fmr LLC - Defense World
Adicet Bio begins trial for kidney cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances with Phase 1 Trial of ADI-270 - TipRanks
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):